Upgrade to SI Premium - Free Trial

Taysha Gene Therapies (TSHA)

5.50 -0.39 (6.62%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/17/26)

Latest Headlines

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 5, 2026 8:01 AM - Globe NewsWire Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Stalfort John A III June 2, 2026 4:31 PM - SEC Filing Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Sepp-Lorenzino Laura June 2, 2026 4:31 PM - SEC Filing Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Long Alison S June 2, 2026 4:30 PM - SEC Filing Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Donenberg Phillip B. June 2, 2026 4:30 PM - SEC Filing Form 8-K Taysha Gene Therapies, For: Jun 01 June 2, 2026 4:06 PM - SEC Filing Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: Vestal Point Capital, LP May 15, 2026 5:13 PM - SEC Filing Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RTW INVESTMENTS, LP May 15, 2026 8:36 AM - SEC Filing Taysha Gene Therapies (TSHA) PT Raised to $10 at BMO Capital May 7, 2026 7:46 AM - StreetInsider Form 10-Q Taysha Gene Therapies, For: Mar 31 May 6, 2026 8:31 AM - SEC Filing Form 8-K Taysha Gene Therapies, For: May 06 May 6, 2026 8:12 AM - SEC Filing Taysha Gene Therapies (TSHA) Misses Q1 EPS by 2c May 6, 2026 8:03 AM - StreetInsider Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update May 6, 2026 8:00 AM - Globe NewsWire Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 1, 2026 4:05 PM - StreetInsider Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 April 29, 2026 8:00 AM - Globe NewsWire Taysha Gene Therapies to present TSHA-102 preclinical data at ASGCT meeting April 27, 2026 5:21 PM - StreetInsider Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting April 27, 2026 5:21 PM - Globe NewsWire Form ARS Taysha Gene Therapies, For: Dec 31 April 22, 2026 8:06 AM - SEC Filing Form DEF 14A Taysha Gene Therapies, For: Jun 01 April 22, 2026 8:03 AM - SEC Filing Form DEFA14A Taysha Gene Therapies, April 22, 2026 8:03 AM - SEC Filing Form 4 Taysha Gene Therapies, For: Apr 10 Filed by: Nagendran Sukumar April 13, 2026 4:34 PM - SEC Filing Form 144 Taysha Gene Therapies, Filed by: Nagendran Sukumar April 10, 2026 4:12 PM - SEC Filing Taysha Gene Therapies (TSHA) PT Raised to $17 at Canaccord April 6, 2026 6:35 AM - StreetInsider Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 3, 2026 8:00 AM - Globe NewsWire Taysha Gene Therapies (TSHA) Reiterated at Overweight by Cantor Fitzgerald on Phase 1/2 Data March 25, 2026 7:22 AM - StreetInsider Taysha Gene Therapies (TSHA) PT Raised to $13 at Jefferies March 19, 2026 4:32 PM - StreetInsider Raymond James Reiterates Strong Buy Rating on Taysha Gene Therapies (TSHA) March 19, 2026 1:54 PM - StreetInsider Form 10-K Taysha Gene Therapies, For: Dec 31 March 19, 2026 8:32 AM - SEC Filing Form 8-K Taysha Gene Therapies, For: Mar 19 March 19, 2026 8:08 AM - SEC Filing Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update March 19, 2026 8:00 AM - StreetInsider Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 March 12, 2026 8:00 AM - StreetInsider Full Article List